Clinical Research Directory
Browse clinical research sites, groups, and studies.
Genomic Risk in Retroperitoneal Sarcoma
Sponsor: Fox Chase Cancer Center
Summary
The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease. Often, tumors recur in locations within the retroperitoneum remote from the original primary tumor. This study hypothesizes that normal appearing retroperitoneal fat actually harbors underlying genetic changes which predispose to development of future liposarcoma. To accomplish this goal, retroperitoneal fat is sampled from quadrants within and remote from the primary tumor and is subsequently subjected to genetic analyses looking for such predisposing factors.
Official title: Characterization of the Genomic Risk Underlying Retroperitoneal Liposarcoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2022-03-07
Completion Date
2027-08-01
Last Updated
2024-05-31
Healthy Volunteers
Yes
Interventions
Biospecimen sample collection during standard-of-care surgery
Patients in this observational study are undergoing planned surgical resection of their retroperitoneal sarcoma as prescribed by their primary surgeon and treatment team. In addition to removal of the primary tumor, surgeons remove 4 samples of retroperitoneal fat and a sample of subcutaneous fat for further study at the time of the operation.
Locations (1)
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States